Ed Allera, shareholder in the firm's FDA & Biotechnology practice, comments in Modern Healthcare about the impact of President Trump's new tariffs on the healthcare industry. Generic drug manufacturers may be hit the hardest, he suggests, potentially inflating prescription prices and insurance premiums and exacerbating the drug shortage problem in the U.S. Read "Tariffs Could Drive Drug and Medical Device Prices Higher."